Dimethyl cardamonin inhibits lipopolysaccharide-induced inflammatory factors through blocking NF-kappaB p65 activation

• Published in: International immunopharmacology Vol. 10; no. 9; pp. 1127 - 1134
• Main Authors: Kim, Young-Joo, Ko, Hyeonseok, Park, Jin-Soo, Han, Im-Ho, Amor, Evangeline C, Lee, Jong Wha, Yang, Hyun Ok
• Format: Journal Article
• Language: English
• Published: Netherlands 01.09.2010
• Subjects: Animals; Anti-Inflammatory Agents - pharmacology; Chalcones - pharmacology; Cyclooxygenase 2 - analysis; Dinoprostone - analysis; Inflammation - drug therapy; Inflammation Mediators - antagonists & inhibitors; Interleukin-1beta - analysis; Interleukin-6 - analysis; Lipopolysaccharides - immunology; Macrophages - drug effects; Male; Mice; Mice, Inbred ICR; Nitric Oxide - analysis; Nitric Oxide Synthase Type II - analysis; Phosphorylation; Shock, Septic - chemically induced; Shock, Septic - drug therapy; Transcription Factor RelA - antagonists & inhibitors; Tumor Necrosis Factor-alpha - analysis

This study has found that dimethyl cardamonin (2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone; DMC), a naturally occurring chalcone, showed potent anti-inflammatory effects in vitro and in vivo. In a cellular model of inflammation, DMC inhibited production of nitric oxide...